THE EFFECT OF THE TIME AND REGULARITY OF ADMINISTRATION OF IMATINIB MESYLATE (GLIVEK) ON SURVIVAL RATE
The data on all the patients revealed in the city of Volgograd and Volgograd region from 1998 till 2009, suffering from the chronic myeloid leukemia, were processed and analyzed. 126 patients from the register were not treated with imatinib, and 103 patients started receiving imatinib at different times from the moment of diagnosis. We revealed a dependence of the length of imatinib therapy on the survival rate. Early onset of treatment (up to 4 months from the moment of diagnosis) has a reliable influence on uneventful survival and determines a tendency for overall survival improvement